Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
20 Octobre 2017 - 5:23AM
Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that
Dr. Frédéric Triebel, Prima’s Chief Scientific Officer &
Medical Officer, will be giving an oral presentation on Prima’s
ongoing TACTI-mel Phase 1 clinical trial in metastatic melanoma at
the World Immunotherapy Congress 2017 in Basel, Switzerland at
5.50pm CEST on October 31, 2017.
The TACTI-mel Phase 1 clinical trial, being undertaken in
Australia, is investigating the use of eftilagimod alpha (IMP321),
the Company’s lead product candidate, in combination with
pembrolizumab (KEYTRUDA) in metastatic melanoma patients. The
patients eligible to participate in the TACTI-mel Phase 1 clinical
trial are those that have either had no response or a suboptimal
response to KEYTRUDA as a monotherapy first-line of treatment.
In addition, Dr. Triebel will provide background information on
LAG-3, IMP321, and the ongoing investigator sponsored INSIGHT
clinical trial that is exploring different routes of administration
of IMP321 in solid tumours.
Prima BioMedPrima BioMed is listed on the
Australian Securities Exchange and on the NASDAQ in the US. For
further information please visit www.primabiomed.com.au.
For further information please
contact:
U.S. Investors:Jay Campbell, Vice President of
Business Development and Investor Relations, Prima Biomed+1 (917)
860-9404; jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646) 378-2933;
mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Immutep Limited (NASDAQ): 0 recent articles
Plus d'articles sur